VXRT - Plucky Underdog Vaxart Still Banging Drum For Oral Vaccination

• Vaxart stock has gained 54% over the past month as the company continues to press its case for an oral COVID vaccine.
• Its phase 1 trial results were considered disappointing but Vaxart has issued a robust response.
• The company is still under investigation for possibly making misleading statements about its inclusion in Operation Warp Speed last June/July.
• Besides COVID, RSV, Influenza, Flu and HPV vaccines are at various stages of development.
• The management team has grown and the company is probably priced correctly at this time, but I see the potential for 50-70% upside long term.

For further details see: